Status:
COMPLETED
A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients
Lead Sponsor:
Novartis
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18+ years
Brief Summary
This was a single-center, retrospective, observational study (non-interventional study with secondary use of data) among patients in a real-world setting. This study used the medical record data from...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Received at least one inclisiran injection during the indexing period.
- Had at least 9 months of follow-up from the index date (had at least one LDL-C assessment during baseline period and at least one LDL-C assessment at 9 months or later).
- Patients signed the informed consent form.
- Exclusion criteria:
- • Participated in any blinded interventional clinical studies anytime during the study period.
Exclusion
Key Trial Info
Start Date :
April 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 10 2024
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06595069
Start Date
April 30 2024
End Date
July 10 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936